Abstract
The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.
Keywords: Blood-brain barrier (BBB), CNS drug delivery, drug transport, targeting.
Central Nervous System Agents in Medicinal Chemistry
Title:Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Volume: 14 Issue: 1
Author(s): Kritika Goyal, Veena Koul, Yashveer Singh and Akshay Anand
Affiliation:
Keywords: Blood-brain barrier (BBB), CNS drug delivery, drug transport, targeting.
Abstract: The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.
Export Options
About this article
Cite this article as:
Goyal Kritika, Koul Veena, Singh Yashveer and Anand Akshay, Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances, Central Nervous System Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1871524914666141030145948
DOI https://dx.doi.org/10.2174/1871524914666141030145948 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Advances in Sub-Micron Particle Based Aerosol Strategies for Efficient Systemic Delivery of Therapeutic Agents
Current Pharmaceutical Design The Heterogeneity of Glioma Stem Cells
Current Signal Transduction Therapy Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Functional Biomarkers: an Approach to Bridge Pharmacokinetics and Pharmacodynamics in Pediatric Clinical Trials
Current Pharmaceutical Design Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Commentary: The Effects of Psychological Stress on Microglial Cells in the Brain
CNS & Neurological Disorders - Drug Targets Preclinical Studies of Alkylureas as Anti-HIV-1 Contraceptive
Current Pharmaceutical Design Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms
Current Medicinal Chemistry The Relevance of Supplemental Vitamin D in Malignancies
Anti-Cancer Agents in Medicinal Chemistry CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population
Drug Metabolism Letters Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets